350 related articles for article (PubMed ID: 30371509)
1. Utility of Combined EZH2, p-ERK1/2, p-STAT, and MYC Expression in the Differential Diagnosis of EZH2-positive Hodgkin Lymphomas and Related Large B-Cell Lymphomas.
Tian X; Xu J; Dorfman DM
Am J Surg Pathol; 2019 Jan; 43(1):102-109. PubMed ID: 30371509
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas.
Tian X; Pelton A; Shahsafaei A; Dorfman DM
Mod Pathol; 2016 Sep; 29(9):1050-7. PubMed ID: 27282353
[TBL] [Abstract][Full Text] [Related]
3. J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Moore EM; Swerdlow SH; Gibson SE
Hum Pathol; 2017 Oct; 68():47-53. PubMed ID: 28851661
[TBL] [Abstract][Full Text] [Related]
4. GATA3 Immunohistochemical Staining in Hodgkin Lymphoma: Diagnostic Utility in Differentiating Classic Hodgkin Lymphoma From Nodular Lymphocyte Predominant Hodgkin Lymphoma and Other Mimicking Entities.
Kezlarian B; Alhyari M; Venkataraman G; Karner K; Inamdar KV; Menon MP
Appl Immunohistochem Mol Morphol; 2019 Mar; 27(3):180-184. PubMed ID: 28877074
[TBL] [Abstract][Full Text] [Related]
5. Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma.
Hartmann S; Döring C; Vucic E; Chan FC; Ennishi D; Tousseyn T; de Wolf-Peeters C; Perner S; Wlodarska I; Steidl C; Gascoyne RD; Hansmann ML
Br J Haematol; 2015 May; 169(3):415-22. PubMed ID: 25644177
[TBL] [Abstract][Full Text] [Related]
6. AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features.
Rodig SJ; Ouyang J; Juszczynski P; Currie T; Law K; Neuberg DS; Rabinovich GA; Shipp MA; Kutok JL
Clin Cancer Res; 2008 Jun; 14(11):3338-44. PubMed ID: 18519761
[TBL] [Abstract][Full Text] [Related]
7. Atypical variants of nodular lymphocyte-predominant Hodgkin lymphoma show low microvessel density and vessels of distention type.
Scheidt V; Hansmann ML; Schuhmacher B; Döring C; Hartmann S
Hum Pathol; 2017 Feb; 60():129-136. PubMed ID: 27816718
[TBL] [Abstract][Full Text] [Related]
8. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features.
Liu Y; Yu K; Li M; Zeng K; Wei J; Li X; Liu Y; Zhao D; Fan L; Yu Z; Wang Y; Li Z; Zhang W; Bai Q; Yan Q; Guo Y; Wang Z; Guo S
Hum Pathol; 2017 Jun; 64():213-221. PubMed ID: 28438623
[TBL] [Abstract][Full Text] [Related]
9. Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma--endpoints of a spectrum of one disease?
Hartmann S; Döring C; Jakobus C; Rengstl B; Newrzela S; Tousseyn T; Sagaert X; Ponzoni M; Facchetti F; de Wolf-Peeters C; Steidl C; Gascoyne R; Küppers R; Hansmann ML
PLoS One; 2013; 8(11):e78812. PubMed ID: 24244368
[TBL] [Abstract][Full Text] [Related]
10. Macrophages in T cell/histiocyte rich large B cell lymphoma strongly express metal-binding proteins and show a bi-activated phenotype.
Hartmann S; Tousseyn T; Döring C; Flüchter P; Hackstein H; Herreman A; Ponzoni M; de Wolf-Peeters C; Facchetti F; Gascoyne RD; Küppers R; Steidl C; Hansmann ML
Int J Cancer; 2013 Dec; 133(11):2609-18. PubMed ID: 23686423
[TBL] [Abstract][Full Text] [Related]
11. Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling.
Tian X; Xu J; Fletcher C; Hornick JL; Dorfman DM
Mod Pathol; 2018 Apr; 31(4):553-561. PubMed ID: 29327713
[TBL] [Abstract][Full Text] [Related]
12. Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphoma.
Xiao Q; Shen N; Hedvat CV; Moskowitz CH; Sussman LK; Filippa DA; Zelenetz AD; Houldsworth J; Chaganti RS; Teruya-Feldstein J
Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):211-5. PubMed ID: 15551733
[TBL] [Abstract][Full Text] [Related]
13. Evolution in the definition and diagnosis of the Hodgkin lymphomas and related entities.
Tousseyn TA; King RL; Fend F; Feldman AL; Brousset P; Jaffe ES
Virchows Arch; 2023 Jan; 482(1):207-226. PubMed ID: 36274093
[TBL] [Abstract][Full Text] [Related]
14. Reactive T cells by flow cytometry distinguish Hodgkin lymphomas from T cell/histiocyte-rich large B cell lymphoma.
Wu D; Thomas A; Fromm JR
Cytometry B Clin Cytom; 2016 Sep; 90(5):424-32. PubMed ID: 26084540
[TBL] [Abstract][Full Text] [Related]
15. Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with CD30-positive lymphocyte-predominant (LP) cells.
Seliem RM; Ferry JA; Hasserjian RP; Harris NL; Zukerberg LR
J Hematop; 2011 Sep; 4(3):175. PubMed ID: 32288859
[TBL] [Abstract][Full Text] [Related]
16. Fascin expression in diffuse large B-cell lymphoma, anaplastic large cell lymphoma, and classical Hodgkin lymphoma.
Bakshi NA; Finn WG; Schnitzer B; Valdez R; Ross CW
Arch Pathol Lab Med; 2007 May; 131(5):742-7. PubMed ID: 17488159
[TBL] [Abstract][Full Text] [Related]
17. Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases.
Shi M; Shahsafaei A; Liu C; Yu H; Dorfman DM
Leuk Lymphoma; 2015 Jul; 56(7):2087-91. PubMed ID: 25263318
[TBL] [Abstract][Full Text] [Related]
18. The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma.
Browne P; Petrosyan K; Hernandez A; Chan JA
Am J Clin Pathol; 2003 Nov; 120(5):767-77. PubMed ID: 14608905
[TBL] [Abstract][Full Text] [Related]
19. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma.
Boudová L; Torlakovic E; Delabie J; Reimer P; Pfistner B; Wiedenmann S; Diehl V; Müller-Hermelink HK; Rüdiger T
Blood; 2003 Nov; 102(10):3753-8. PubMed ID: 12881319
[TBL] [Abstract][Full Text] [Related]
20. Utility of LRF/Pokemon and NOTCH1 protein expression in the distinction between nodular lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma.
Bohn O; Maeda T; Filatov A; Lunardi A; Pandolfi PP; Teruya-Feldstein J
Int J Surg Pathol; 2014 Feb; 22(1):6-11. PubMed ID: 24326827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
